Cassava Sciences Inc
NASDAQ:SAVA

  • LAST PRICE
    19.6300
  • TODAY'S CHANGE (%)
    -0.3100 (-1.5547%)
  • Bid / Lots
    19.6000/ 1
  • Ask / Lots
    19.8900/ 5
  • Open / Previous Close
    19.7300 / 19.9400
  • Day Range
    19.4201
    19.9400
  • 52 Week Range
    12.3202
    32.1000
  • Volume
    775,736

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
SAVA
Cassava Sciences Inc
1.1B
-16.8x
---
ELVN
Enliven Therapeutics Inc
1.1B
-10.9x
---
PHVS
Pharvaris NV
1.0B
-6.1x
---
AUTL
Autolus Therapeutics PLC
1.1B
-3.3x
---
VRNA
Verona Pharma PLC
978.7M
-15.3x
---
DAWN
Day One Biopharmaceuticals Inc
1.2B
-5.1x
---
As of 2024-06-07

Company Information

Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

Contact Information

Headquarters
6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX, United States 78731
Phone
512-501-2444
Fax
512-614-0414

Executives

Chairman of the Board, President, Chief Executive Officer
Remi Barbier
Chief Financial Officer
Eric Schoen
Senior Vice President, General Counsel
R. Christopher Cook
Chief Medical Officer
James Kupiec
Lead Independent Director
Sanford Robertson

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.0B
Revenue (TTM)
$0.00
Shares Outstanding
48.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.47
EPS
$-1.17
Book Value
$3.25
P/E Ratio
-16.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.